Social networks
298 10,888Activities
Technologies
Entity types
Location
Edmund Halley Rd, Littlemore, Oxford OX4, UK
The Oxford Science Park
United Kingdom
Employees
Scale: 51-200
Estimated: 124
Engaged corporates
4Added in Motherbase
3 years agoNIOX Group plc is a dedicated diagnostics and monitoring company focused on respiratory disease.
NIOX Group plc is a company that specialises in the development, manufacture, and distribution of medical devices for the diagnosis and monitoring of asthma. Their flagship product, NIOX VERO®, is a non-invasive medical device that measures fractional exhaled nitric oxide (FeNO) levels in patients with asthma.
NIOX VERO® provides accurate and reliable results, allowing healthcare
professionals to make informed decisions about the diagnosis and management of asthma. It is easy to use, and can be used in a variety of settings, including clinics, hospitals, and primary care settings.
The NIOX Group plc is committed to improving the lives of people with asthma and is dedicated to innovation and excellence in its products and services. NIOX® is also committed to offering additional training and support for healthcare professionals.
Overall, NIOX Group plc is the global leader in FeNO testing, with a strong
reputation for innovation and excellence in the development of medical devices for the diagnosis and management of asthma. With NIOX VERO®, healthcare professionals have a reliable and non-invasive tool to help them better diagnose and manage asthma.
References:
1. Alving K et al. Validation of a new portable exhaled nitric oxide analyzer, NIOX VERO®: randomized studies in asthma. Pulm Ther. 2017;3:207-218.
2. Gao J et al. Association between fractional exhaled nitric oxide, sputum induction and peripheral blood eosinophil in uncontrolled asthma. Allergy, Asthma & Clinical Immunology. 2018;1
3. Busse WW et al. Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis. Lancet Respir Med. 2021;9(10):1165-1173.
4. Menzies-Gow A et al. Clinical utility of fractional exhaled nitric oxide in severe asthma management. Eur Respir J. 2020;55(3):1901633.
5. NIOX®. Data on File; MKT-DOF-007.
FeNO testing, NIOX®, Asthma management, and Asthma diagnosis
Find out more about NIOX VERO®, the gold standard FeNO analyser from NIOX®, the world-leader in FeNO testing – NIOX.com
Corporate | Type | Tweets | Articles | |
---|---|---|---|---|
Intuitive Medical Device, Medical Equipment Manufacturing | Intuitive Medical Device, Medical Equipment Manufacturing | Other 23 Jul 2021 | | |
Oxford Science Enterprises Startup accelerator & VC, Venture Capital and Private Equity Principals | Oxford Science Enterprises Startup accelerator & VC, Venture Capital and Private Equity Principals | Other 2 Apr 2019 | | |
London Stock Exchange Finance, Financial Services | London Stock Exchange Finance, Financial Services | Not capitalistic Not partnership Event 20 Mar 2014 | | |
IP Group plc Financial Services | IP Group plc Financial Services | Other 2 Apr 2019 | |